AI Stock Analysis - Ocugen (OCGN)
Analysis generated August 26, 2025.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to address rare and underserved conditions. The company's pipeline includes gene therapies, biologics, and vaccines. Ocugen has gained attention for its work on the Covaxin vaccine for COVID-19 in collaboration with Bharat Biotech. This focus on innovative treatments targets significant unmet medical needs, positioning Ocugen in a niche yet promising segment of the healthcare industry.
Stock Alerts - Ocugen (OCGN)
 |
Ocugen | March 13 Price is up by 6.8% in the last 24h. |
|
Ocugen | March 11 Price is up by 11% in the last 24h. |
|
Ocugen | March 10 Price is up by 6.9% in the last 24h. |
|
Ocugen | March 6 Price is down by -6.3% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Ocugen
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 54 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2,104 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 154,368 | Sign up | Sign up | Sign up |
| X Followers | 62,259 | Sign up | Sign up | Sign up |
| X Mentions | 94 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $10,000 | Sign up | Sign up | Sign up |
| Business Outlook | 39 | Sign up | Sign up | Sign up |
| Linkedin Employees | 117 | Sign up | Sign up | Sign up |
About Ocugen
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”.
| Price | $2.48 |
| Target Price | Sign up |
| Volume | 5,437,616 |
| Market Cap | $813M |
| Year Range | $0.96 - $2.48 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy PipelineMarch 11 - Yahoo Entertainment |
|
Ocugen Q4 Earnings Call HighlightsMarch 4 - Yahoo Entertainment |
|
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial ResultsMarch 4 - GlobeNewswire |
|
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis PigmentosaMarch 2 - GlobeNewswire |
|
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsFebruary 18 - GlobeNewswire |
|
Ocugen Appoints Rita Johnson-Greene to Chief Financial OfficerFebruary 9 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 1.8M | 0 | 1.8M | -20M | -18M | -0.070 |
| Q2 '25 | 1.4M | 0 | 1.4M | -15M | -13M | -0.050 |
| Q1 '25 | 1.5M | 0 | 1.5M | -15M | -14M | -0.050 |
| Q4 '24 | 760,000 | 600,000 | 760,000 | -14M | -13M | -0.050 |
| Q3 '24 | 1.1M | 0 | 1.1M | -13M | -13M | -0.050 |
Insider Transactions View All
| Fernandes Prabhavathi filed to buy 10,000 shares at $0.9. December 2 '24 |
| Castillo Kirsten filed to buy 75,000 shares at $0.9. November 26 '24 |
| Zhang Junge filed to buy 1,077,182 shares at $0.5. June 16 '23 |
| Musunuri Shankar filed to sell 2,190,073 shares at $1.1. February 17 '23 |
| Musunuri Shankar filed to sell 2,227,950 shares at $1.3. January 19 '23 |
Similar companies
Read more about Ocugen (OCGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Ocugen
The Market Cap of Ocugen is $813M.
Currently, the price of one share of Ocugen stock is $2.48.
The OCGN stock price chart above provides a comprehensive visual representation of Ocugen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ocugen shares. Our platform offers an up-to-date OCGN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Ocugen (OCGN) does not offer dividends to its shareholders. Investors interested in Ocugen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Ocugen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
